Every 8-K that Maze Therapeutics, Inc. (MAZE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MAZE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAZE filings page.
Maze Therapeutics, Inc. announced that its Board appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, effective August 13, 2026. Dr. Johnson’s term runs to the 2028 annual stockholders’ meeting and Dr. Kornowski’s to 2029, each continuing until a successor is elected or earlier departure events occur. Dr. Johnson joins the nominating and corporate governance committee, while Dr. Kornowski joins the audit and compensation committees.
Each new non-employee director receives compensation under Maze’s director policy, including a pro rata portion of the $40,000 annual cash retainer plus applicable committee retainers and an option to purchase 36,000 shares of common stock, vesting in equal monthly installments over 36 months from the appointment date. The Board also reclassified existing directors Nancy C. Andrews, M.D., Ph.D. and Hervé Hoppenot between Class II and Class III to rebalance the three director classes, with revised terms expiring at the 2027 and 2028 annual meetings, respectively.
Maze Therapeutics, Inc. reported second quarter 2026 results and pipeline updates. The company is advancing Phase 2 programs for MZE829 in APOL1-mediated kidney disease and MZE782 in phenylketonuria and chronic kidney disease, with multiple data readouts and a pivotal trial for MZE829 planned from late 2026 through 2027, subject to regulatory feedback.
Maze reported a net loss of $44.7 million for the quarter, or $0.76 per share$494.9 million as of June 30, 2026, supported by an April 2026 equity and pre-funded warrant offering of approximately $150 million in gross proceeds. Maze states that this cash position is expected to fund operations into 2029.
Maze Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting. A total of 44,660,029 shares of common stock, representing approximately 89.75% of the shares entitled to vote, were present or represented by proxy, establishing a quorum.
Stockholders elected Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as directors to serve until the 2029 annual meeting, with 35,792,536 and 34,056,425 votes for, respectively, and broker non-votes recorded on both. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,557,778 votes for, 728 against, and 101,523 abstentions.
Maze Therapeutics, Inc. reported that Amy Bachrodt, its Senior Vice President of Finance, has given notice that she will resign effective June 1, 2026. The company states her resignation is not due to any disagreement regarding operations, policies, practices, or financial reporting. Following her departure, Chief Financial Officer Misbah Tahir will also serve as the company’s principal accounting officer, consolidating financial leadership under the CFO role.
Maze Therapeutics reported first quarter 2026 results alongside important clinical and financing updates. The company generated $20.0 million in license revenue from a milestone tied to its MZE001 partnership, while R&D and G&A expenses rose to $34.1 million and $12.4 million, respectively.
Net loss narrowed to $24.2 million, or $0.45 per share, from $32.8 million, or $1.15 per share, a year earlier. Cash, cash equivalents and marketable securities were $362.9 million as of March 31, 2026, and the company highlighted a strong balance sheet of $528 million including April financing and milestone proceeds, supporting an expected cash runway into 2029.
Clinically, Maze reported positive topline Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, showing meaningful reductions in proteinuria and no serious treatment-related adverse events, and it plans a pivotal trial in moderate AMKD without diabetes. Phase 2 proof-of-concept trials for MZE782 in PKU and CKD are planned to initiate in 2026.
Maze Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC for a registered public offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants to purchase 850,000 shares at $23.499 per warrant. The company expects gross proceeds of $150 million and estimates net proceeds of about $144.7 million after fees and expenses.
The pre-funded warrants carry a $0.001 per share exercise price and are exercisable any time, subject to beneficial ownership caps generally at 4.99% or 9.99%, adjustable up to 19.99% with advance notice. Maze plans to use the funds primarily to advance its clinical-stage programs MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, and for general corporate purposes. The company states that, with these proceeds and existing cash and investments, it expects to fund operations into 2029.
Maze Therapeutics reported a pivotal year, combining strong clinical progress with a fortified balance sheet. The company announced positive Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, showing a 35.6% mean proteinuria reduction at week 12 and no serious treatment-related safety issues, and plans to advance the drug into a pivotal program.
Maze is also preparing two Phase 2 proof-of-concept trials for MZE782 in phenylketonuria and chronic kidney disease in 2026, and recorded a $20 million milestone from partner Shionogi tied to the Phase 2 ESPRIT trial of Pompe candidate MZE001. Cash, cash equivalents and marketable securities reached $360.0 million as of December 31, 2025, providing expected runway into 2028.
For 2025, Maze reported a net loss of $131.1 million as it increased R&D spending to $108.4 million and G&A to $34.5 million, compared with prior-year license revenue of $167.5 million that had produced net income. The company also strengthened governance by appointing BridgeBio founder and CEO Neil Kumar to its Board of Directors, with an equity grant vesting over three years.
Maze Therapeutics, Inc. entered into a senior secured term loan agreement with Hercules Capital providing up to $200.0 million in potential borrowing capacity. An initial $40.0 million tranche was funded at closing, generating approximately $38.4 million of net proceeds after fees.
The facility matures on February 1, 2031, carries a floating interest rate based on the Wall Street Journal prime rate with floors between 7.95% and 9.25%, and offers an interest-only period of up to 48 months, or up to 60 months if specified milestones are met. Repayments trigger an exit fee of 3.95% to 6.45% of principal, and early prepayments can incur premiums of up to 3.00% within the first 12 months.
The loan is secured by a first lien on substantially all of Maze’s assets and includes customary representations, covenants, financial tests, and events of default, including minimum unrestricted cash requirements tied to market capitalization and outstanding loan balances. Concurrently, the company terminated its prior Loan and Security Agreement with Banc of California and released that lender’s security interest in its assets.
Maze Therapeutics, Inc. filed a current report to note it issued a press release with its financial results for the third quarter ended September 30, 2025.
The press release, dated November 6, 2025, is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” limiting its treatment under certain securities law liability provisions.
Maze Therapeutics appointed Mr. Hoppenot to the Board and named him Chairman effective October 6, 2025. As a non-employee director he will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $30,000 annual chairman retainer for the remainder of the year under the companys existing policy. The Board also granted an option to purchase up to 36,000 shares of common stock (the Option Award), with 1/36th of the underlying shares vesting and becoming exercisable on each monthly anniversary of the Appointment Date, subject to continued service.
The arrangement combines cash retainer compensation paid pro rata for partial-year service with an equity award that vests monthly over 36 months, tying compensation to ongoing service while spreading equity delivery across a multi-year period.
Maze Therapeutics reported a private placement of pre-funded warrants to raise capital and provided related registration rights and disclosures. The company sold pre-funded warrants to purchase up to 5,231,090 shares of common stock at a purchase price of $16.249 per pre-funded warrant, with each warrant exercisable for $0.001 per share and not expiring. The company agreed to file a registration statement for resale of the shares within 60 days of closing and to use reasonable best efforts to have it declared effective within 75 days of initial filing. The filing states the securities were sold without registration and only to accredited investors for investment purposes. Exhibits include forms of the warrant, purchase agreement and registration rights agreement, plus press releases announcing the private placement and MZE782 data dated September 11, 2025. The filing also contains standard forward-looking statement language identifying programs MZE829 and MZE782 and listing development, regulatory, funding and macroeconomic risks.
Maze Therapeutics announced the appointment of Misbah Tahir as Chief Financial Officer and principal financial officer, effective September 2, 2025. The company disclosed key compensation terms in an offer letter: an initial annual base salary of $500,000, an annual discretionary bonus opportunity up to 40% of base salary, a one-time sign-on bonus of $50,000 (subject to clawback if service is under one year), and an equity option to purchase up to 325,000 shares that vests 25% after one year and then 1/48th monthly thereafter. The filing notes the appointment relates to Maze's Form 10-Q for the quarter ending September 30, 2025.
Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.